| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S12253-018-0467-8 |
| P698 | PubMed publication ID | 30220022 |
| P2093 | author name string | A Fucic | |
| Z Culig | |||
| A Aghajanyan | |||
| N Le Novere | |||
| P2860 | cites work | Icaritin suppresses development of neuroendocrine differentiation of prostate cancer through inhibition of IL-6/STAT3 and Aurora kinase A pathways in TRAMP mice. | Q53784890 |
| [Correlation between the expression of Pim-1 and androgen-deprivation therapy for prostate cancer]. | Q53810020 | ||
| Hormonal and reproductive factors and pancreatic cancer risk: a prospective cohort study. | Q54515706 | ||
| Genetic variants in AR and SHBG and resistance to hormonal castration in prostate cancer | Q58835397 | ||
| MUC1, MUC2, MUC4, MUC5AC and MUC6 Expression in the Progression of Prostate Cancer | Q60300117 | ||
| Mesothelin and GPR30 Staining Among a Spectrum of Pancreatic Epithelial Neoplasms | Q61772037 | ||
| Pancreatic cancer and androgen metabolism: high androstenedione and low testosterone serum levels | Q68596091 | ||
| Androgen receptor in human normal and malignant pancreatic tissue and cell lines | Q70027186 | ||
| Androstanediol glucuronide in patients with pancreatic cancer and in those with chronic pancreatitis | Q71716464 | ||
| Sex-steroid enzymes, aromatase and 5 alpha-reductase in the pancreas: a comparison of normal adult, foetal and malignant tissue | Q71735464 | ||
| Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer | Q80352321 | ||
| Expression patterns of epithelial-mesenchymal transition markers in localized prostate cancer: significance in clinicopathological outcomes following radical prostatectomy | Q85305829 | ||
| Diabetes and pancreatic cancer | Q85600847 | ||
| Prostate-specific membrane antigen as a marker of pancreatic cancer cells | Q87193518 | ||
| Latent hypothyreosis as a clinical biomarker for therapy response under abiraterone acetate therapy | Q95511311 | ||
| High expression of L-type amino acid transporter 1 (LAT1) predicts poor prognosis in pancreatic ductal adenocarcinomas | Q39583239 | ||
| Sonic and desert hedgehog signaling in human fetal prostate development | Q39630855 | ||
| Icariin is more potent than genistein in promoting osteoblast differentiation and mineralization in vitro | Q39782095 | ||
| Castration resistance of prostate cancer cells caused by castration-induced oxidative stress through Twist1 and androgen receptor overexpression. | Q39791652 | ||
| Interleukin-6 regulates androgen synthesis in prostate cancer cells | Q39819739 | ||
| Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer | Q39954334 | ||
| Androgen receptor blockade in experimental combination therapy of pancreatic cancer | Q40121837 | ||
| Wnt3a growth factor induces androgen receptor-mediated transcription and enhances cell growth in human prostate cancer cells. | Q40479983 | ||
| Prevention of metastatic pancreatic cancer growth in vivo by induction of apoptosis with genistein, a naturally occurring isoflavonoid | Q40661388 | ||
| Concurrent Diabetes Mellitus may Negatively Influence Clinical Progression and Response to Androgen Deprivation Therapy in Patients with Advanced Prostate Cancer | Q40782810 | ||
| SRD5A gene polymorphism in Japanese men predicts prognosis of metastatic prostate cancer with androgen-deprivation therapy | Q41591542 | ||
| A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. | Q41615181 | ||
| Follicle-stimulating hormone: A potential surrogate marker for androgen deprivation therapy oncological and systemic effects | Q41764150 | ||
| P300 inhibition enhances gemcitabine-induced apoptosis of pancreatic cancer | Q41816428 | ||
| Wnt/β-Catenin-Responsive Cells in Prostatic Development and Regeneration. | Q41958748 | ||
| Breaking a paradigm: IL-6/STAT3 signaling suppresses metastatic prostate cancer upon ARF expression. | Q42729905 | ||
| Inhibition of Plk1 represses androgen signaling pathway in castration-resistant prostate cancer | Q43211192 | ||
| Alterations in cholesterol regulation contribute to the production of intratumoral androgens during progression to castration-resistant prostate cancer in a mouse xenograft model | Q43252963 | ||
| Evaluation of androgen, estrogen (ER alpha and ER beta), and progesterone receptor expression in human prostate cancer by real-time quantitative reverse transcription-polymerase chain reaction assays | Q43561126 | ||
| Transactivation of ErbB2 and ErbB3 by tumor necrosis factor-alpha and anisomycin leads to impaired insulin signaling through serine/threonine phosphorylation of IRS proteins | Q43847035 | ||
| IGFBP2 Activates the NF-κB Pathway to Drive Epithelial-Mesenchymal Transition and Invasive Character in Pancreatic Ductal Adenocarcinoma | Q43990089 | ||
| Expression of kallikrein-related peptidase 7 predicts poor prognosis in patients with unresectable pancreatic ductal adenocarcinoma | Q44497447 | ||
| Serum sex steroids depict a nonlinear u-shaped association with high-risk prostate cancer at radical prostatectomy | Q44908788 | ||
| Neuroendocrine differentiation in castration-resistant prostate cancer: a systematic diagnostic attempt. | Q45023641 | ||
| HER2 overexpression correlates with survival after curative resection of pancreatic cancer. | Q46016285 | ||
| Pancreatic cancer and medical history in a population-based case-control study in the San Francisco Bay Area, California | Q46584309 | ||
| Effect of androgen deprivation therapy in the thyroid function test of patients with prostate cancer | Q46646911 | ||
| Tissue-specific promoter utilisation of the kallikrein-related peptidase genes, KLK5 and KLK7, and cellular localisation of the encoded proteins suggest roles in exocrine pancreatic function | Q46829746 | ||
| Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma | Q47950548 | ||
| Sex hormone levels in the serum of patients with pancreatic adenocarcinoma. | Q50957518 | ||
| Epidemiology of castration resistant prostate cancer: a longitudinal analysis using a UK primary care database. | Q51330993 | ||
| Possible Role of HER-2 in the Progression of Prostate Cancer from Primary Tumor to Androgen Independence. | Q53322439 | ||
| Global cancer statistics | Q22241238 | ||
| Next generation sequencing of prostate cancer from a patient identifies a deficiency of methylthioadenosine phosphorylase, an exploitable tumor target | Q24608574 | ||
| Cancer of the Pancreas: Molecular Pathways and Current Advancement in Treatment | Q26740619 | ||
| Clinicopathological Implications of Wingless/int1 (WNT) Signaling Pathway in Pancreatic Ductal Adenocarcinoma | Q26766122 | ||
| Mechanisms of resistance in castration-resistant prostate cancer (CRPC) | Q26774221 | ||
| Notch signaling in prostate cancer: refining a therapeutic opportunity | Q26777624 | ||
| Prostate cancer stem cells: the role of androgen and estrogen receptors | Q26778415 | ||
| Insulin-like growth factor (IGF)-I and IGF binding proteins axis in diabetes mellitus | Q26801855 | ||
| Androgen receptor signaling in hepatocellular carcinoma and pancreatic cancers | Q27004276 | ||
| Immune checkpoint and inflammation as therapeutic targets in pancreatic carcinoma | Q28069864 | ||
| Concordant loss of MTAP and p16/CDKN2A expression in pancreatic intraepithelial neoplasia: evidence of homozygous deletion in a noninvasive precursor lesion | Q28245326 | ||
| Ack1 tyrosine kinase activation correlates with pancreatic cancer progression | Q28259414 | ||
| Pim-1 kinase as cancer drug target: An update | Q28273475 | ||
| The Systems Biology Graphical Notation | Q29617466 | ||
| Reconstituting pancreas development from purified progenitor cells reveals genes essential for islet differentiation | Q30542144 | ||
| Structural analysis of the ErbB-2 receptor using monoclonal antibodies: Implications for receptor signalling | Q30885329 | ||
| Dynamic regulation of estrogen receptor-beta expression by DNA methylation during prostate cancer development and metastasis | Q31065757 | ||
| Local aromatase expression in human prostate is altered in malignancy | Q33202613 | ||
| The androgen receptor can signal through Wnt/beta-Catenin in prostate cancer cells as an adaptation mechanism to castration levels of androgens | Q33316388 | ||
| Enhancer RNAs participate in androgen receptor-driven looping that selectively enhances gene activation | Q33665345 | ||
| Molecular signaling pathways that regulate prostate gland development | Q33666315 | ||
| A case-control study of reproductive factors, female hormone use, and risk of pancreatic cancer | Q33954763 | ||
| Ran GTPase protein promotes metastasis and invasion in pancreatic cancer by deregulating the expression of AR and CXCR4. | Q33989971 | ||
| Inhibition of polo-like kinase 1 (Plk1) enhances the antineoplastic activity of metformin in prostate cancer | Q34042731 | ||
| Pancreatic ductal adenocarcinoma: risk factors, screening, and early detection | Q34093790 | ||
| Biology of prostate-specific antigen | Q34170171 | ||
| Pancreas: a sex steroid-dependent tissue | Q34285258 | ||
| Risk factors for pancreatic cancer: underlying mechanisms and potential targets | Q34400723 | ||
| The role of estrogen receptor β in prostate cancer | Q34416254 | ||
| Targeting GPR30 with G-1: a new therapeutic target for castration-resistant prostate cancer | Q34518031 | ||
| Oestrogen receptor proteins in malignant and fetal pancreas | Q34782981 | ||
| Estradiol in elderly men. | Q34800127 | ||
| Signaling and transcriptional control of pancreatic organogenesis | Q34801929 | ||
| Constitutively active AR-V7 plays an essential role in the development and progression of castration-resistant prostate cancer | Q34883636 | ||
| Fine mapping the KLK3 locus on chromosome 19q13.33 associated with prostate cancer susceptibility and PSA levels | Q34975896 | ||
| Prostate cancer: another aspect of the insulin-resistance syndrome? | Q35012809 | ||
| Pancreatic cancer biology and genetics | Q35013204 | ||
| Structure-function studies of the bHLH phosphorylation domain of TWIST1 in prostate cancer cells | Q35024079 | ||
| IL-6 promotes prostate tumorigenesis and progression through autocrine cross-activation of IGF-IR. | Q35037290 | ||
| The versatile functions of Sox9 in development, stem cells, and human diseases | Q35077784 | ||
| Phase I Study of Anti-CD3 x Anti-Her2 Bispecific Antibody in Metastatic Castrate Resistant Prostate Cancer Patients. | Q35157412 | ||
| Androgens as therapy for androgen receptor-positive castration-resistant prostate cancer | Q35207110 | ||
| MUC1 selectively targets human pancreatic cancer in orthotopic nude mouse models. | Q35225232 | ||
| Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors | Q35532230 | ||
| Characterisation of oestrogen receptor, progesterone receptor, trefoil factor 1, and epidermal growth factor and its receptor in pancreatic cystic neoplasms and pancreatic ductal adenocarcinoma | Q35595131 | ||
| Serum follicle-stimulating hormone levels predict time to development of castration-resistant prostate cancer | Q35683334 | ||
| The CXCL12/CXCR4 axis promotes ligand-independent activation of the androgen receptor | Q35838409 | ||
| A novel nuclear Src and p300 signaling axis controls migratory and invasive behavior in pancreatic cancer | Q35875878 | ||
| IL-6 stimulates STAT3 and Pim-1 kinase in pancreatic cancer cell lines | Q35916583 | ||
| Minireview: transcriptional regulation in pancreatic development | Q35986764 | ||
| Mechanisms of the development of androgen independence in prostate cancer | Q36072079 | ||
| Differential regulation of androgen receptor by PIM-1 kinases via phosphorylation-dependent recruitment of distinct ubiquitin E3 ligases. | Q36080362 | ||
| From estrogen to androgen receptor: a new pathway for sex hormones in prostate | Q36090546 | ||
| Hypothyroidism in Pancreatic Cancer: Role of Exogenous Thyroid Hormone in Tumor Invasion-Preliminary Observations | Q36795562 | ||
| Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth | Q36876865 | ||
| Inverse association between serum insulin and sex hormone-binding globulin in a population survey in Sweden | Q36924538 | ||
| Regulation of cell apoptosis and proliferation in pancreatic cancer through PI3K/Akt pathway via Polo-like kinase 1. | Q36983840 | ||
| Targeting hexokinase 2 in castration-resistant prostate cancer | Q36997881 | ||
| Plk1 phosphorylation of orc2 and hbo1 contributes to gemcitabine resistance in pancreatic cancer. | Q37066064 | ||
| The steroid receptor coactivator-3 is required for the development of castration-resistant prostate cancer | Q37068054 | ||
| Omeprazole Inhibits Pancreatic Cancer Cell Invasion through a Nongenomic Aryl Hydrocarbon Receptor Pathway | Q37104022 | ||
| PIM-1 contributes to the malignancy of pancreatic cancer and displays diagnostic and prognostic value | Q37233255 | ||
| Expression of aldo-keto reductase family 1 member C3 (AKR1C3) in neuroendocrine tumors & adenocarcinomas of pancreas, gastrointestinal tract, and lung | Q37277775 | ||
| p53 and p16Ink4a/p19Arf Loss Promotes Different Pancreatic Tumor Types from PyMT-Expressing Progenitor Cells | Q37280291 | ||
| The what, where, when and how of Wnt/β-catenin signaling in pancreas development | Q37309133 | ||
| Treatment-dependent androgen receptor mutations in prostate cancer exploit multiple mechanisms to evade therapy | Q37396357 | ||
| Localization of receptors for luteinizing hormone-releasing hormone in pancreatic and mammary cancer cells | Q37510495 | ||
| TWIST1 hypermethylation is observed in pancreatic cancer | Q37642045 | ||
| Clinical and molecular characterization of HER2 amplified-pancreatic cancer. | Q37690146 | ||
| The 5α-androstanedione pathway to dihydrotestosterone in castration-resistant prostate cancer | Q37953805 | ||
| FOXA1: a transcription factor with parallel functions in development and cancer. | Q37960622 | ||
| LHRH Agonists for the Treatment of Prostate Cancer: 2012. | Q38061629 | ||
| PIM1 kinase as a target in prostate cancer: roles in tumorigenesis, castration resistance, and docetaxel resistance. | Q38165990 | ||
| Adverse effects of androgen-deprivation therapy in prostate cancer and their management | Q38261253 | ||
| Diagnosis and molecular aspects of solid-pseudopapillary neoplasms of the pancreas | Q38294183 | ||
| Neuroendocrine differentiation of prostate cancer: a review | Q38326554 | ||
| Suppression of growth and tumorigenicity in the prostate tumor cell line M12 by overexpression of the transcription factor SOX9. | Q38342587 | ||
| Sonic hedgehog-responsive genes in the fetal prostate | Q38357999 | ||
| Current perspectives on FOXA1 regulation of androgen receptor signaling and prostate cancer | Q38538387 | ||
| Metformin and prostate cancer stem cells: a novel therapeutic target | Q38555403 | ||
| Intra-endodermal interactions are required for pancreatic beta cell induction. | Q38622943 | ||
| The Aurora-A-Twist1 axis promotes highly aggressive phenotypes in pancreatic carcinoma. | Q38717592 | ||
| Global incidence and mortality of pancreatic diseases: a systematic review, meta-analysis, and meta-regression of population-based cohort studies | Q38731062 | ||
| Bazedoxifene as a Novel GP130 Inhibitor for Pancreatic Cancer Therapy | Q38734014 | ||
| Desmoplasia suppression by metformin-mediated AMPK activation inhibits pancreatic cancer progression | Q38735802 | ||
| Hypoxia induces TWIST-activated epithelial-mesenchymal transition and proliferation of pancreatic cancer cells in vitro and in nude mice | Q38735959 | ||
| Concurrent Androgen and Estrogen Ablation and Inhibition of Steroid Biosynthetic Enzyme Treatment for Castration-resistant Prostate Cancer | Q38755244 | ||
| Epigenetic regulation of KLK7 gene expression in pancreatic and cervical cancer cells | Q38765682 | ||
| SOX9 drives WNT pathway activation in prostate cancer | Q38780862 | ||
| AMPed up to treat prostate cancer: novel AMPK activators emerge for cancer therapy | Q38833054 | ||
| Crosstalk between epithelial-mesenchymal transition and castration resistance mediated by Twist1/AR signaling in prostate cancer | Q38840477 | ||
| Cooperativity and equilibrium with FOXA1 define the androgen receptor transcriptional program | Q38990293 | ||
| Insulin-like growth factor-I induces CLU expression through Twist1 to promote prostate cancer growth. | Q39027755 | ||
| Systems oncology: A new paradigm in cancer research | Q39144506 | ||
| Pancreatic stellate cell secreted IL-6 stimulates STAT3 dependent invasiveness of pancreatic intraepithelial neoplasia and cancer cells | Q39414719 | ||
| Androgen receptor and nutrient signaling pathways coordinate the demand for increased amino acid transport during prostate cancer progression. | Q39456571 | ||
| The Genomic Landscape of Pancreatic and Periampullary Adenocarcinoma | Q39527587 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | prostate cancer | Q181257 |
| P304 | page(s) | 1269-1277 | |
| P577 | publication date | 2018-09-16 | |
| P1433 | published in | Pathology Oncology Research | Q26842743 |
| P1476 | title | Systems Oncology: Bridging Pancreatic and Castrate Resistant Prostate Cancer | |
| P478 | volume | 25 |
| Q92541944 | Anakoinosis: Correcting Aberrant Homeostasis of Cancer Tissue-Going Beyond Apoptosis Induction | cites work | P2860 |
Search more.